Antitumoral effect of a vaccination procedure with an autologous hemoderivative

Cancer Biology and Therapy

Volumn 2, Issue 2, 2003, Pages 155-160

  Lasalvia Prisco, Eduardo ^a,b,c   Cucchi, Silvia ^c   Vázquez, Jesús ^b   Lasalvia Galante, Eduardo ^b   Golomar, Wilson ^b   Gordon, William ^c  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b National Cancer Institute   (Uruguay)

^c PharmaBlood Inc   (United States)

Author keywords

Autologous vaccine; Cancer; Cancer immunotherapy; Cancer vaccine; Hemoderivative vaccine

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

AGED; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECRETION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

AGED; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; STROMAL CELLS; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 79960831065     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.2.247     Document Type: Article

References (28)

1. Berd D, Kairys J, Dunton Ch, Mastrangelo MJ, Sato T, Maguire H (1998) Autologous, Hapten-Modified Vaccine as a Treatment for Human Cancers. Seminars in Oncology 1998; 25:646.
2. Amato RJ, Wood LS, Savary Ch, Wood Ch, Hawkins EA, Reitsma DG, Srivastava P (1999) Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor-Derived Heat Shock Protein-Peptide Complex (HSPPC-96) With or Without Interleukin-2 (IL-2). 35th Annual meeting of the ASCO, May.
3. Menoret A, Bell G. Purification of multiple heat shock proteins from a single tumor sample. J Immunology Methods 2000; 237:119.
4. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis, JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived Heat shock protein gp96 preparations: A pilot study. Int J Cancer 2000; 88:232.
5. Lewis JJ, Janetzki S, Livingston PhO, Desantis D, Williams L, Klimstra D, et al. Pilot Trial of Vaccination with Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex (HSPPC-96) in Patients with Resected Pancreatic Adenocarcinoma. 35th Annual meeting of the ASCO, May, 1999.
6. Chan AD, Morton DL (1998) Active Immunotherapy With Allogeneic Tumor Cell Vaccines: Present Status. Seminars in Oncology 1998; 25:611.
7. Lasalvia E, Cucchi S, DeStefani E, Deneo H, Fierro L, Mechoso B, et al. Inducción autóloga de fibrogénesis tumoral (Autologous Induction of tumor fibrogenesis). Neoplasia (Spain) 1995; 1:5.
8. Lasalvia E, Cucchi S, Carlevaro T, Vázquez J, Riotorto R, Fierro L. Anti-metastatic effect of a blood fraction from cancer patients. 31st Annual meeting of the ASCO, May 1995: A730.
9. Berd D, Mastrangelo MJ, Engstron P. Augmentation of the Human Immune Response by Cyclophosphamide. Cancer Res 1982; 42:4862.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
11. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998; 95:4589.
12. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts'o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer 2000; 88:2787.
13. Wu JT. Review of circulating tumors markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene. Ann Clin Lab Sci 1999; 29:106.
14. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity; Blood 2001 97:3505-12.
15. Blachere NE, Li Z, Chandawarkar RY, Basu S, Jaikaria NS, Udono H, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte Response and tumor immunity. J Exp Med 1997; 186:1315.
16. Moroi Y, Mayhew M, Trcka J, Joe MH, Takecchi Y, Hartl FU, et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000; 97:3485.
17. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 1997; 12:165.
18. Feldweg AM, Srivastava PK. Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96. Int J Cancer 1995; 63:310.
19. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp 70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999; 162:1730.
20. Multhoff G, Botzler C, Wiesnet M, Muller E, Wilmanns W, Issels RD. A stress-inducible heat-shock protein (HSP72) is expressed on the surface of tumor cells, but not on normal cells. Int J Cancer 1995; 61:272.
21. Lehner T, Bergmeier LA, Wang Y, Tao L, Sing M, Spallek R, et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 2000; 30:594.
22. Gu X, Ko MK, Kay EP. Intracellular interaction of Hsp 47 and type I collagen in corneal endothelial cells. Invest Ophthalmol Vis Sci 1999; 40:289.
23. Kuroda K, Tsukifuji R, Shinkai H. Increased expression of heat shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. J Invest Dermatol 1998; 111:1023.
24. Razzaque MS, Nazneen A, Taguchi T. Immunolocalization of collagen-binding heat shock protein 47 in fibrotic lung disease. Mod Pathol 1998; 11:1183.
25. Antoniades HN, Scher ChD, Stiles ChD. Purification of Human platelet-derived growth factor. Proc Natl Acad Sci USA 1979; 76:1809.
26. Saetang T, Suttijitpaisal P, Ratanabanangkoon K. Preparations of toxic components from Naja kaouthia venom by selective heat denaturation. J Nat Toxins 1998; 7:37-44. (Pubitemid 28233196)
27. Leong SP, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22:166.
28. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19:309.